BioNano Genomics (NASDAQ:BNGO) Shares Gap Up to $1.02

BioNano Genomics Inc (NASDAQ:BNGO)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $0.66, but opened at $1.02. BioNano Genomics shares last traded at $0.91, with a volume of 126,889 shares trading hands.

A number of brokerages have issued reports on BNGO. Zacks Investment Research downgraded BioNano Genomics from a “hold” rating to a “sell” rating in a research note on Monday, September 23rd. ValuEngine upgraded BioNano Genomics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Maxim Group restated a “buy” rating and issued a $7.00 price objective on shares of BioNano Genomics in a research note on Friday, August 9th.

The company has a debt-to-equity ratio of 3.13, a quick ratio of 2.77 and a current ratio of 3.17. The company has a market cap of $16.94 million, a P/E ratio of -0.34 and a beta of 1.06. The firm has a 50 day moving average price of $0.92 and a two-hundred day moving average price of $2.16.

BioNano Genomics (NASDAQ:BNGO) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.14). The firm had revenue of $2.18 million for the quarter, compared to the consensus estimate of $2.56 million. BioNano Genomics had a negative return on equity of 347.02% and a negative net margin of 247.03%. On average, sell-side analysts predict that BioNano Genomics Inc will post -2.55 EPS for the current fiscal year.

BioNano Genomics Company Profile (NASDAQ:BNGO)

Bionano Genomics, Inc operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics.

Featured Story: Why Invest in Dividend Achievers?

Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with's FREE daily email newsletter.